Dimorphic metabolic and endocrine disorders in mice lacking the constitutive androstane receptor.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 12 2019
27 12 2019
Historique:
received:
14
08
2019
accepted:
08
12
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
29
12
2019
Statut:
epublish
Résumé
Metabolic diseases such as obesity, type II diabetes and hepatic steatosis are a public health concern in developed countries. The metabolic risk is gender-dependent. The constitutive androstane receptor (CAR), which is at the crossroads between energy metabolism and endocrinology, has recently emerged as a promising therapeutic agent for the treatment of obesity and type 2 diabetes. In this study we sought to determine its role in the dimorphic regulation of energy homeostasis. We tracked male and female WT and CAR deficient (CAR-/-) mice for over a year. During aging, CAR-/- male mice developed hypercortisism, obesity, glucose intolerance, insulin insensitivity, dyslipidemia and hepatic steatosis. Remarkably, the latter modifications were absent, or minor, in female CAR-/- mice. When ovariectomized, CAR-/- female mice developed identical patterns of metabolic disorders as observed in male mice. These results highlight the importance of steroid hormones in the regulation of energy metabolism by CAR. They unveil a sexually dimorphic role of CAR in the maintenance of endocrine and metabolic homeostasis underscoring the importance of considering sex in treatment of metabolic diseases.
Identifiants
pubmed: 31882815
doi: 10.1038/s41598-019-56570-0
pii: 10.1038/s41598-019-56570-0
pmc: PMC6934754
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20169Commentaires et corrections
Type : ErratumIn
Références
Arch Toxicol. 2015 Jul;89(7):1045-55
pubmed: 25975989
Diabetes Res. 1989 Feb;10(2):85-92
pubmed: 2501061
Front Horm Res. 2016;46:54-65
pubmed: 27212264
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18831-6
pubmed: 19850873
Cell Rep. 2018 Mar 6;22(10):2690-2701
pubmed: 29514097
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
J Biol Chem. 2000 May 19;275(20):15122-7
pubmed: 10748001
Endocr Rev. 2013 Jun;34(3):309-38
pubmed: 23460719
J Biol Chem. 2006 Sep 8;281(36):26540-51
pubmed: 16825189
J Clin Endocrinol Metab. 2016 Jan;101(1):103-13
pubmed: 26574953
Sci Rep. 2016 Feb 16;6:20127
pubmed: 26879573
J Endocrinol. 2017 Jan;232(1):29-36
pubmed: 27647861
Mol Endocrinol. 2000 Nov;14(11):1897-905
pubmed: 11075820
Ann N Y Acad Sci. 2011 Jul;1229:29-37
pubmed: 21793836
Nature. 1998 Oct 8;395(6702):612-5
pubmed: 9783588
J Biol Chem. 2004 May 7;279(19):19832-8
pubmed: 15004031
Mol Endocrinol. 2004 Jul;18(7):1589-98
pubmed: 14988430
Environ Health Perspect. 2018 Jun 25;126(6):067007
pubmed: 29950287
Cell Metab. 2017 Mar 7;25(3):499-505
pubmed: 28190772
Mol Aspects Med. 2013 Feb;34(1):1-11
pubmed: 23068073
Cell Mol Neurobiol. 2019 Mar;39(2):169-180
pubmed: 30656469
Drug Metab Dispos. 2007 Sep;35(9):1700-10
pubmed: 17576804
PLoS One. 2016 Mar 09;11(3):e0148308
pubmed: 26959975
Hepatology. 2001 May;33(5):1232-8
pubmed: 11343253
Diabetes. 2015 Feb;64(2):447-58
pubmed: 25239636
Mol Cell Endocrinol. 2018 Aug 15;471:75-88
pubmed: 28774777
J Clin Invest. 1997 Mar 1;99(5):846-54
pubmed: 9062341
J Clin Invest. 2011 Jan;121(1):431-41
pubmed: 21123945
J Biol Chem. 2009 Sep 18;284(38):25984-92
pubmed: 19617349
Mol Biol Rep. 2013 Feb;40(2):1241-7
pubmed: 23079705
J Biol Chem. 2003 May 9;278(19):17277-83
pubmed: 12611900
Endocrinology. 2005 Mar;146(3):995-1002
pubmed: 15564320
J Endocrinol. 2012 Feb;212(2):111-27
pubmed: 21903862
Diabetes. 1985 Sep;34(9):911-6
pubmed: 3896900
Arch Biochem Biophys. 2003 Jan 1;409(1):207-11
pubmed: 12464260